Long-Term Donor-Site Morbidity Following Entire Sural Nerve Harvest for Grafting.
Brachial plexus palsy
donor-site morbidity
sensory deficit
sural nerve harvest
Journal
The Journal of hand surgery
ISSN: 1531-6564
Titre abrégé: J Hand Surg Am
Pays: United States
ID NLM: 7609631
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
16
12
2022
revised:
31
01
2023
accepted:
10
03
2023
medline:
7
11
2023
pubmed:
6
11
2023
entrez:
3
11
2023
Statut:
ppublish
Résumé
The sural nerve is the autologous nerve used most commonly for grafting. However, recent studies indicate a high rate of complications and complaints after sural nerve removal. In this prospective study, we evaluated donor-site morbidity following full-length sural nerve harvesting on long-term follow-up. Fifty-one legs from 43 patients who underwent complete sural nerve harvesting for brachial plexus reconstruction were included in the study. After an average of 5 years, with a minimum postoperative follow-up of 12 months, sensory deficits in the leg and foot were analyzed using 2.0-g monofilaments. Regions of sensory deficit were marked with a skin marker and photographed. Over these regions of decreased sensation, we tested nociception using an eyebrow tweezer. Patients were also asked about pain, cold intolerance, pruritis, difficulties walking, and foot swelling. Regions most affected (84% of patients) were over the calcaneus and cuboid. However, in these regions, nociception was preserved. Regions of decreased sensation extended to the calf region in 11 of 51 legs. In 13 patients, we also observed regions of decreased sensation on the proximal leg. In five feet, the sensation was entirely preserved. No patient had any complaints about pain, cold intolerance, itchiness, difficulties walking, or foot swelling. Decreased sensation with nociception preserved was most common along the lateral side of the foot over the calcaneus and cuboid. Removing the entire sural nerve produced no long-term complaints of pain. Sural nerve use appears safe. Therapeutic II.
Identifiants
pubmed: 37923488
pii: S0363-5023(23)00140-5
doi: 10.1016/j.jhsa.2023.03.009
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1173.e1-1173.e7Informations de copyright
Copyright © 2023. Published by Elsevier Inc.